Media headlines about Glaukos Corporation (NYSE:GKOS) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Glaukos Corporation earned a news impact score of 0.15 on Accern’s scale. Accern also gave news stories about the medical instruments supplier an impact score of 45.3483628720434 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:

Shares of Glaukos Corporation (NYSE GKOS) traded up 0.79% during mid-day trading on Wednesday, reaching $37.20. The company had a trading volume of 307,585 shares. The firm’s 50 day moving average is $38.96 and its 200-day moving average is $42.96. Glaukos Corporation has a 12-month low of $28.72 and a 12-month high of $52.49. The stock’s market capitalization is $1.28 billion.

Several analysts have recently weighed in on GKOS shares. Zacks Investment Research lowered Glaukos Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, May 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $54.00 price target on shares of Glaukos Corporation in a research note on Thursday, May 4th. TheStreet lowered Glaukos Corporation from a “c” rating to a “d+” rating in a research note on Wednesday, May 3rd. Stephens raised Glaukos Corporation from an “equal weight” rating to an “overweight” rating in a research note on Monday, May 8th. Finally, BidaskClub lowered Glaukos Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. Glaukos Corporation has a consensus rating of “Buy” and an average price target of $52.33.

TRADEMARK VIOLATION NOTICE: This piece was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at

In other news, Director Orbimed Advisors Llc sold 325,000 shares of the company’s stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $37.93, for a total value of $12,327,250.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 16.40% of the company’s stock.

Glaukos Corporation Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Insider Buying and Selling by Quarter for Glaukos Corporation (NYSE:GKOS)

Receive News & Stock Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related stocks with our FREE daily email newsletter.